BioNeutra Global Corporation
BGACF
$0.0608
$0.0386173.87%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -29.35% | -27.16% | -26.29% | -15.90% | -5.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -29.35% | -27.16% | -26.29% | -15.90% | -5.87% |
| Cost of Revenue | -21.52% | -19.08% | -17.84% | -14.93% | -17.28% |
| Gross Profit | -61.60% | -62.51% | -56.48% | -20.07% | 118.03% |
| SG&A Expenses | -9.88% | -2.60% | -12.20% | -27.13% | -18.90% |
| Depreciation & Amortization | 227.99% | 443.67% | -18.58% | -39.90% | -200.60% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.22% | -11.97% | -16.22% | -19.43% | -20.28% |
| Operating Income | -105.44% | -114.90% | -65.82% | 34.90% | 63.96% |
| Income Before Tax | -90.36% | -129.88% | -183.93% | 1.34% | 51.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -90.36% | -129.88% | -183.93% | 1.34% | 51.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.36% | -129.88% | -183.93% | 1.34% | 51.49% |
| EBIT | -105.44% | -114.90% | -65.82% | 34.90% | 63.96% |
| EBITDA | -549.37% | -637.04% | -320.36% | 37.74% | 88.74% |
| EPS Basic | -89.37% | -129.19% | -184.07% | 1.24% | 51.47% |
| Normalized Basic EPS | -16.32% | -58.76% | -52.85% | 31.54% | 41.59% |
| EPS Diluted | -86.49% | -125.93% | -163.14% | 1.76% | 51.04% |
| Normalized Diluted EPS | -16.32% | -58.76% | -52.85% | 31.54% | 41.59% |
| Average Basic Shares Outstanding | 0.40% | 0.27% | 0.13% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.40% | 0.27% | 0.13% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
